Total Payments
$1.1M
2024 Payments
$23,520
Companies
5
Transactions
320
Medicare Patients
13,063
Medicare Billing
$697,391
Payment Breakdown by Category
Consulting$1.0M (95.3%)
Research$32,990 (3.1%)
Other$9,250 (0.9%)
Travel$8,255 (0.8%)
Food & Beverage$346.73 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.0M | 292 | 95.3% |
| Unspecified | $32,990 | 7 | 3.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,250 | 5 | 0.9% |
| Travel and Lodging | $8,255 | 13 | 0.8% |
| Food and Beverage | $346.73 | 3 | 0.0% |
Payments by Type
General
$1.0M
313 transactions
Research
$32,990
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $879,270 | 256 | $0 (2021) |
| PFIZER INC. | $130,200 | 35 | $0 (2019) |
| Siemens Medical Solutions USA, Inc. | $32,851 | 22 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $25,420 | 6 | $0 (2024) |
| EMD Serono, Inc. | $7,570 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,520 | 6 | Siemens Medical Solutions USA, Inc. ($15,000) |
| 2023 | $16,900 | 1 | Regeneron Pharmaceuticals, Inc. ($16,900) |
| 2021 | $267,398 | 64 | Merck Sharp & Dohme Corporation ($264,885) |
| 2020 | $118,370 | 49 | Merck Sharp & Dohme Corporation ($118,370) |
| 2019 | $158,548 | 89 | Merck Sharp & Dohme Corporation ($125,330) |
| 2018 | $319,830 | 67 | Merck Sharp & Dohme Corporation ($259,940) |
| 2017 | $170,745 | 44 | Merck Sharp & Dohme Corporation ($110,745) |
All Payment Transactions
320 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/26/2024 | Siemens Medical Solutions USA, Inc. | NAEOTOM Alpha (Device) | Consulting Fee | Cash or cash equivalent | $15,000.00 | General |
| Category: CT and RO incl. Computed Tomography and Radiation Oncology | ||||||
| 08/01/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $60.00 | Research |
| Study: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 06/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $60.00 | Research |
| Study: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 06/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $120.00 | Research |
| Study: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 02/29/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 01/05/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $6,780.00 | Research |
| Study: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 11/22/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $16,900.00 | Research |
| Study: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES • Category: ONCOLOGY | ||||||
| 12/27/2021 | Siemens Medical Solutions USA, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| 12/27/2021 | Siemens Medical Solutions USA, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,213.41 | General |
| 12/27/2021 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | Cash or cash equivalent | $49.66 | General |
| 12/21/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $340.00 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $170.00 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $10,800.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,850.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $220.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $920.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $115.00 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $85.00 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $13,860.00 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,430.00 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $10,320.00 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $75.00 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $11,580.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES | Regeneron Pharmaceuticals, Inc. | $25,420 | 6 |
| EMR 100070-005 | EMD Serono, Inc. | $7,570 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 3,575 | 23,647 | $1.2M | $166,230 |
| 2022 | 8 | 3,715 | 30,636 | $1.6M | $201,000 |
| 2021 | 9 | 3,167 | 31,304 | $1.3M | $179,203 |
| 2020 | 10 | 2,606 | 31,005 | $1.0M | $150,958 |
Total Patients
13,063
Total Services
116,592
Medicare Billing
$697,391
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 71260 | Ct scan of chest with contrast | Office | 2023 | 403 | 497 | $534,063 | $53,072 | 9.9% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 273 | 298 | $262,703 | $30,015 | 11.4% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 584 | 653 | $157,374 | $28,951 | 18.4% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 448 | 468 | $107,172 | $19,196 | 17.9% |
| 71045 | X-ray of chest, 1 view | Facility | 2023 | 1,215 | 1,854 | $68,598 | $13,571 | 19.8% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2023 | 115 | 115 | $41,496 | $8,013 | 19.3% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Office | 2023 | 38 | 38 | $23,930 | $6,057 | 25.3% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Facility | 2023 | 61 | 61 | $13,086 | $3,310 | 25.3% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 206 | 15,579 | $15,579 | $1,757 | 11.3% |
| 71046 | X-ray of chest, 2 views | Facility | 2023 | 174 | 177 | $7,788 | $1,425 | 18.3% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 36 | 37 | $3,019 | $471.23 | 15.6% |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | Office | 2023 | 22 | 3,870 | $3,870 | $393.05 | 10.2% |
| 71260 | Ct scan of chest with contrast | Office | 2022 | 587 | 708 | $741,008 | $73,631 | 9.9% |
| 71250 | Ct scan of chest without contrast | Office | 2022 | 307 | 330 | $307,527 | $34,044 | 11.1% |
| 71260 | Ct scan of chest with contrast | Facility | 2022 | 672 | 732 | $178,608 | $31,565 | 17.7% |
| 71250 | Ct scan of chest without contrast | Facility | 2022 | 424 | 441 | $100,989 | $17,944 | 17.8% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Office | 2022 | 75 | 75 | $43,917 | $11,358 | 25.9% |
| 71045 | X-ray of chest, 1 view | Facility | 2022 | 916 | 1,269 | $47,989 | $9,591 | 20.0% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2022 | 113 | 113 | $40,410 | $8,288 | 20.5% |
| 70491 | Ct scan of soft tissue of neck with contrast | Office | 2022 | 40 | 41 | $37,103 | $4,211 | 11.3% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Facility | 2022 | 71 | 71 | $14,939 | $3,934 | 26.3% |
| 70491 | Ct scan of soft tissue of neck with contrast | Facility | 2022 | 58 | 59 | $16,625 | $2,762 | 16.6% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2022 | 299 | 26,642 | $70,018 | $2,378 | 3.4% |
| 71046 | X-ray of chest, 2 views | Facility | 2022 | 123 | 125 | $5,390 | $944.41 | 17.5% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 30 | 30 | $2,208 | $350.08 | 15.9% |
About Dr. Subba Digumarthy, MD
Dr. Subba Digumarthy, MD is a Diagnostic Radiology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689623886.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Subba Digumarthy, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $23,520 received in 2024. These payments were reported across 320 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($1.0M).
As a Medicare-enrolled provider, Digumarthy has provided services to 13,063 Medicare beneficiaries, totaling 116,592 services with total Medicare billing of $697,391. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Boston, MA
- Active Since 05/08/2006
- Last Updated 08/09/2012
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1689623886
Products in Payments
- KEYTRUDA (Biological) $879,270
- LORBRENA (Drug) $70,200
- LIBTAYO (Biological) $25,420
- NAEOTOM Alpha (Device) $15,000
- Bavencio (Biological) $7,570
- SOMATOM Force (Device) $6,402
- SOMATOM GO (Device) $749.10
- SOMATOM Definition (Device) $381.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Boston
Andrew Kompel, M.d, M.D
Diagnostic Radiology — Payments: $3.4M
Diagnostic Radiology $3.4M
Gregg Miller, M.d, M.D
Diagnostic Radiology — Payments: $3.0M
Diagnostic Radiology $3.0M
Stephan Anderson, M.d, M.D
Diagnostic Radiology — Payments: $2.4M
Diagnostic Radiology $2.4M
Ashraf Thabet, M.d, M.D
Diagnostic Radiology — Payments: $1.7M
Diagnostic Radiology $1.7M
Dr. Mukesh Harisinghani, Md, MD
Diagnostic Radiology — Payments: $1.4M
Diagnostic Radiology $1.4M
Dr. Ronald Arellano, Md, MD
Diagnostic Radiology — Payments: $853,391
Diagnostic Radiology $853,391